Pharming Group (NASDAQ:PHAR) Shares Gap Down to $9.91

Pharming Group (NASDAQ:PHAR) shares gapped down before the market opened on Tuesday . The stock had previously closed at $9.91, but opened at $9.36. Pharming Group shares last traded at $9.36, with a volume of 589 shares changing hands.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 14th.

Pharming Group Stock Performance

The business has a 50 day moving average price of $10.79 and a two-hundred day moving average price of $11.40. The stock has a market cap of $655.66 million, a P/E ratio of -66.85 and a beta of 0.16. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.62.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.08). Pharming Group had a negative return on equity of 4.53% and a negative net margin of 4.13%. The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $71.83 million. On average, sell-side analysts forecast that Pharming Group will post -0.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Orion Portfolio Solutions LLC bought a new stake in shares of Pharming Group (NASDAQ:PHAR) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 11,715 shares of the company’s stock, valued at approximately $134,000. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.